Peter Diamandis, MD’s Longevity Protocol
About Peter Diamandis
Evidence Rating Key
🚀 The Diamandis Framework: “Bridge to the Future”
Diamandis frames his entire protocol around one concept: Longevity Escape Velocity (LEV) — the point at which medical science advances faster than you age, potentially leading to radical life extension. His protocol is not about optimal supplementation in isolation; it is about staying alive and healthy long enough to intercept the next decade of breakthroughs in AI medicine, gene therapy, and cellular rejuvenation.
This framing explains why he is the most aggressive of all influencers in this series on Rx interventions (rapamycin, metformin) and also the most commercially invested in longevity infrastructure. Every supplement recommendation comes with the implicit context: “this is your bridge to 2035.”
Evidence Ratings
★★★★☆ Good evidence
★★★☆☆ Moderate/mixed
★★☆☆☆ Weak/anecdotal
★☆☆☆☆ Experimental only
💊 Personal Stack — Tier 1: Prescription Drugs (Medical Supervision Required)
Diamandis is the most vocal proponent of off-label rapamycin use of any public longevity figure. He calls it “the most impactful longevity intervention available today.”
| Drug | Protocol | Rationale | Evidence | Peer comparison |
|---|---|---|---|---|
| Rapamycin ⭐ | 6 mg once weekly · 3 months on / 1 month off · TruAge testing before & after | mTOR inhibition → autophagy, immune modulation; +14–60% lifespan in mice1 | ★★★☆☆ | Sinclair: cautious. Johnson: discontinued (side effects). Attia: stopped recommending. Patrick: not taking. Diamandis: most committed advocate. |
| Metformin ER | 1,000 mg/day · Evening, after dinner | AMPK activation; insulin sensitivity; anti-inflammatory; TAME trial target2 | ★★★★☆ | Sinclair: takes it. Attia: stopped (exercise adaptation concern). Johnson: reduced. Patrick: not taking. |
🧬 The Hallmarks of Aging Framework
Diamandis explicitly organises his stack around the 12 Hallmarks of Aging (originally 9, identified in Cell 2013, expanded to 12). Each supplement/drug targets one or more hallmarks. This makes his approach more systematic than most influencers, though it still relies heavily on animal and mechanistic data.
💊 Personal Stack — Tier 2: Core Daily Supplements
| Supplement | Dose | Hallmark targeted | Evidence |
|---|---|---|---|
| NMN (NAD+ precursor) | 500–1,000 mg/day | Genomic instability, mitochondrial dysfunction, epigenetics | ★★★☆☆ |
| Vitamin D3 + K2 | 5,000 IU D3 / 200 mcg K2 MK-7 | Immune function, bone; testing-guided dosing | ★★★★★ |
| Omega-3 (EPA+DHA) | 2–4 g/day | Altered intercellular communication, inflammation | ★★★★★ |
| CoQ10 (Ubiquinol) | 200–400 mg/day | Mitochondrial dysfunction | ★★★★☆ |
| Quercetin + Fisetin (senolytics) | Quercetin 500 mg + Fisetin 100 mg; pulsed dosing | Cellular senescence — clears zombie cells | ★★★☆☆ |
| Creatine | 5 g pre-workout | Mitochondrial energy, muscle preservation | ★★★★★ |
| Magnesium | 400 mg/day (glycinate or threonate) | Sleep, metabolic health, 300+ enzymatic reactions | ★★★★★ |
| Alpha Lipoic Acid | 600 mg/day | Oxidative stress, mitochondrial support, reduces AGEs | ★★★☆☆ |
| Lion’s Mane mushroom | 500–1,000 mg/day | NGF stimulation; cognitive protection; neuroprotection | ★★★☆☆ |
| Cal/Mag Butyrate + Probiotic | Butyrate 600–1,000 mg; Probiotic daily | Dysbiosis / gut microbiome; inflammation via SCFA signalling | ★★★★☆ |
| Arterosil (glycocalyx) | Per label | Endothelial glycocalyx regeneration; vascular health — unique to Diamandis stack3 | ★★☆☆☆ |
| Selenium | 100–200 mcg/day | Antioxidant; thyroid function; selenoprotein synthesis | ★★★★☆ |
🏛️ Abundance 360 (A360): What Diamandis Recommends to Members
Distinct from his personal 75-pill stack, Diamandis curates a more accessible protocol through A360 and Fountain Life — designed for executives who want the highest-leverage interventions without full personalisation. These are his public-facing recommendations.
Diamandis’s most distinctive recommendation: before any supplement, get comprehensive diagnostics. Fountain Life’s APEX programme ($25,000–$50,000+) includes full-body MRI, liquid biopsy cancer screening, coronary CT, microbiome, comprehensive bloodwork, and genetic panel. His philosophy: “You can’t optimise what you don’t measure.” This is categorically different from every other influencer in this series — he requires measurement before intervention.
Every year at A360, Diamandis leads a group 22-day sugar elimination via WhatsApp. The community accountability model is intentional — he cites research on group behaviour change. After 3 weeks, sugar cravings diminish and the brain recalibrates toward whole food preferences. His reasoning: “Sugar is as addictive as cocaine in rat models” — citing Mark Hyman, MD.
Zone 2 cardio (fat-burning, low-intensity aerobic, 130–140 bpm) plus heavy resistance training. Pre-workout creatine (5g) before every heavy session. He also uses apps like J&J 7-Min Workout for daily movement when time-constrained.
Consistent bedtime, cool room, no alcohol. Uses sleep tracking (Oura or Whoop) for objective data. He frames poor sleep as “the single fastest route to accelerated aging” — aligning with Johnson and Patrick on sleep as the foundation.
A360’s non-supplement recommendation: treat your health like a business. Hire a medical team, track KPIs (biomarkers), make evidence-based adjustments, plan for exponential improvement. This is Diamandis’s most unique contribution — applying Silicon Valley founder thinking to personal biology.
💰 Commercial Interests: Most Deeply Invested of All Influencers
Diamandis has the most significant financial stake in longevity of any influencer in this series. His relevant companies:
- Fountain Life — diagnostics clinics charging $25K–$50K+ per APEX programme. He recommends comprehensive testing first; his company provides it.
- Lifeforce — supplements and health coaching subscription service. Supplement recommendations align with Lifeforce product lines.
- BOLD Capital Partners — $600M+ deployed into longevity startups. He has financial upside from the entire industry succeeding.
- A360/Platinum — $25,000–$100,000/year programmes where longevity protocols are a core deliverable.
Unlike Brecka or Johnson, Diamandis’s conflicts are systemic rather than supplement-specific — he profits from the entire longevity ecosystem rather than specific products. This makes his general advocacy for the field credible but his specific clinical recommendations worth scrutinising for self-referential recommendations (e.g. Fountain Life testing).
Footnotes
- Rapamycin lifespan extension: Harrison DE et al., Nature 2009 (14%/9% extension in mice). Kaeberlein lab: 60% increase in remaining life expectancy in middle-aged mice. PEARL human trial (2024): first RCT in healthy adults — early data, 1-year duration, results mixed. Johnson discontinued rapamycin in 2024; Attia no longer recommends it for most patients. Diamandis remains the most public advocate.
- Metformin TAME trial: Targeting Aging with Metformin — the first FDA-approved clinical trial specifically for aging as a condition. Diamandis frequently cites this as validation of the pharmacological approach to aging.
- Arterosil: Supports regeneration of the endothelial glycocalyx (the inner lining of blood vessels). Small but growing body of evidence. Unique to Diamandis’s stack — not mentioned by Attia, Sinclair, Huberman, Patrick, or Johnson.
Changelog
- Mar 2026 — Page created. Primary sources: diamandis.com/longevity-full-book, diamandis.com/blog/why-i-take-75-pills-per-day, Longevity Guidebook (2024), rapamycin.news community analysis, nuchido.com review.
Sources
Compare Other Protocols
Rapamycin divergence is the sharpest split in the series: Diamandis is its most committed advocate; Johnson abandoned it; Attia has pulled back; Patrick never took it. On NMN, Diamandis aligns with Sinclair and Johnson. The Hallmarks of Aging framework makes Diamandis’s stack the most systematically organised, even if the evidence behind individual compounds remains uneven.
📋 Protocol Change Log
March 2026 — Protocol page updated with latest publicly shared information.